Antidepressant-Induced Manic Conversion: A Developmentally Informed Synthesis of the Literature

International Review of Neurobiology

Volumn 65, Issue , 2005, Pages 25-52

  Lim, Christine J ^a   Leckman, James F ^b   Young, Christopher ^b,c   Martin, Andrés ^b,c  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT;

ADOLESCENT; ADULT; ANIMAL; BIPOLAR DISORDER; CHEMICALLY INDUCED DISORDER; CHILD; DEPRESSION; HUMAN; REVIEW;

ADOLESCENT; ADULT; ANIMALS; ANTIDEPRESSIVE AGENTS; BIPOLAR DISORDER; CHILD; DEPRESSION; HUMANS;

EID: 26944432760     PISSN: 00747742     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0074-7742(04)65002-1     Document Type: Review

References (135)

1. Achamallah N.S., and Decker D.H. Mania induced by fluoxetine in an adolescent patient. Am. J. Psychiatry 148 (1991) 1404
2. Akiskal H.S. Developmental pathways to bipolarity: Are juvenile-onset depressions pre-bipolar?. J. Am. Acad. Child Adolesc. Psychiatry 34 (1995) 754-763
3. Akiskal H.S., Walker P., Puzantian V.R., King D., Rosenthal T.L., and Dranon M. Bipolar outcome in the course of depressive illness. Phenomenologic, familial, and pharmacologic predictors. J. Affect. Disord. 5 (1983) 115-128
4. Alda M. Genetic factors and treatment of mood disorders. Bipolar Disord. 3 (2001) 318-324
5. Altshuler L., Suppes T., Black D., Nolen W.A., Keck Jr. P.E., Frye M.A., McElroy S., Kupka R., Grunze H., Walden J., Leverich G., Denicoff K., Luckenbaugh D., and Post R. Impact of antidepressant discontinuation after acute bipolar depression remission on rates of depressive relapse at 1-year follow-up. Am. J. Psychiatry 160 (2003) 1252-1262
6. Altshuler L.L., Post R.M., Leverich G.S., Mikalauskas K., Rosoff A., and Ackerman L. Antidepressant-induced mania and cycle acceleration: A controversy revisited. Am. J. Psychiatry 152 (1995) 1130-1138
7. Amsterdam J.D., Garcia-Espana F., Fawcett J., Quitkin F.M., Reimherr F.W., Rosenbaum J.F., Schweizer E., and Beasley C. Efficacy and safety of fluoxetine in treating bipolar II major depressive episode. J. Clin. Psychopharmacol. 18 (1998) 435-440
8. Amsterdam J.D., Shults J., Brunswick D.J., and Hundert M. Short-term fluoxetine monotherapy for bipolar type II or bipolar NOS major depression-low manic switch rate. Bipolar Disord. 6 (2004) 75-81
9. Ansorge M.S., Zhou M., Lira A., Hen R., and Gingrich J.A. Early-life blockade of the 5-HT transporter alters emotional behavior in adult mice. Science 306 (2004) 879-881
10. APA. Practice guideline for the treatment of patients with bipolar disorder. Am. J. Psychiatry 151 (1994) 1-36
11. APA. Practice guideline for the treatment of patients with major depressive disorder (revision). Am. J. Psychiatry 157 (2000) 1-45
12. Biederman J., Mick E., Spencer T.J., Wilens T.E., and Faraone S.V. Therapeutic dilemmas in the pharmacotherapy of bipolar depression in the young. J. Child Adolesc. Psychopharmacol. 10 (2000) 185-192
13. Bijl R.V., Ravelli A., and van Zessen G. Prevalence of psychiatric disorder in the general population: Results of The Netherlands Mental Health Survey and Incidence Study (NEMESIS). Soc. Psychiatry Psychiatr. Epidemiol. 33 (1998) 587-595
14. Birmaher B., Brent D.A., and Benson R.S. Summary of the practice parameters for the assessment and treatment of children and adolescents with depressive disorders. J. Am. Acad. Child Adolesc. Psychiatry 37 (1998) 1234-1238
15. Bottlender R., Rudolf D., Strauss A., and Moller H.J. Mood-stabilisers reduce the risk of developing antidepressant-induced maniform states in acute treatment of bipolar I depressed patients. J. Affect. Disord. 63 (2001) 79-83
16. Burke K.C., Burke Jr. J.D., Regier D.A., and Rae D.S. Age at onset of selected mental disorders in five community populations. Arch. Gen. Psychiatry 47 (1990) 511-518
17. Carlson G.A., and Mick E. Drug-induced disinhibition in psychiatrically hospitalized children. J. Child Adolesc. Psychopharmacol. 13 (2003) 153-163
18. Carrey N.J., Dursun S., Clements R., Renton K., Waschbusch D., and MacMaster F.P. Noradrenergic and serotonergic neuroendocrine responses in prepubertal, peripubertal, and postpubertal rats pretreated with desipramine and sertraline. J. Am. Acad. Child Adolesc. Psychiatry 41 (2002) 999-1006 ; discussion 1007-1009.
19. Cicero D., El-Mallakh R.S., Holman J., and Robertson J. Antidepressant exposure in bipolar children. Psychiatry 66 (2003) 317-322
20. Cohen B.M., and Baldessarini R.J. Tolerance to therapeutic effects of antidepressants. Am. J. Psychiatry 142 (1985) 489-490
21. Compton S.N., March J.S., Brent D., Albano A.M.T., Weersing R., and Curry J. Cognitive-behavioral psychotherapy for anxiety and depressive disorders in children and adolescents: An evidence-based medicine review. J. Am. Acad. Child Adolesc. Psychiatry 43 (2004) 930-959
22. Cook E.H., Wagner K.D., March J.S., Biederman J., Landau P., Wolkow R., and Messig M. Long-term sertraline treatment of children and adolescents with obsessive-compulsive disorder. J. Am. Acad. Child Adolesc. Psychiatry 40 (2001) 1175-1181
23. Coryell W., Solomon D., Turvey C., Keller M., Leon A.C., Endicott J., Schettler P., Judd L., and Mueller T. The long-term course of rapid-cycling bipolar disorder. Arch. Gen. Psychiatry 60 (2003) 914-920
24. Costello E.J., Angold A., Burns B.J., Stangl D.K., Tweed D.L., Erkanli A., and Worthman C.M. The Great Smoky Mountains Study of Youth. Goals, design, methods, and the prevalence of DSM-III-R disorders. Arch. Gen. Psychiatry 53 (1996) 1129-1136
25. Coupland N.J., Bell C.J., and Potokar J.P. Serotonin reuptake inhibitor withdrawal. J. Clin. Psychopharmacol. 16 (1996) 356-362
26. Donaldson S.R. Tolerance to phenelzine and subsequent refractory depression: Three cases. J. Clin. Psychiatry 50 (1989) 33-35
27. Dunner D.L., and Fieve R.R. Clinical factors in lithium carbonate prophylaxis failure. Arch. Gen. Psychiatry 30 (1974) 229-233
28. Emslie G.J., Heiligenstein J.H., Wagner K.D., Hoog S.L., Ernest D.E., Brown E., Nilsson M., and Jacobson J.G. Fluoxetine for acute treatment of depression in children and adolescents: A placebo-controlled, randomized clinical trial. J. Am. Acad. Child Adolesc. Psychiatry 41 (2002) 1205-1215
29. Emslie G.J., Rush A.J., Weinberg W.A., Kowatch R.A., Carmody T., and Mayes T.L. Fluoxetine in child and adolescent depression: Acute and maintenance treatment. Depress. Anxiety 7 (1998) 32-39
30. Emslie G.J., Rush A.J., Weinberg W.A., Kowatch R.A., Hughes C.W., Carmody T., and Rintelmann J. A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Arch. Gen. Psychiatry 54 (1997) 1031-1037
31. Faraone S.V., Biederman J., Mennin D., Wozniak J., and Spencer T. Attention-deficit hyperactivity disorder with bipolar disorder: A familial subtype?. J. Am. Acad. Child Adolesc. Psychiatry 36 (1997) 1378-1387 ; discussion 1387-1390.
32. Fava G.A., and Mangelli L. Mania associated with venlafaxine discontinuation. Int. J. Neuropsychopharmacol. 6 (2003) 89-90
33. Fava M., Rappe S.M., Pava J.A., Nierenberg A.A., Alpert J.E., and Rosenbaum J.F. Relapse in patients on long-term fluoxetine treatment: Response to increased fluoxetine dose. J. Clin. Psychiatry 56 (1995) 52-55
34. Fava M., Schmidt M.E., Zhang S., Gonzales J., Raute N.J., and Judge R. Treatment approaches to major depressive disorder relapse. Part 2: Reinitiation of antidepressant treatment. Psychother. Psychosom. 71 (2002) 195-199
35. FDA. FDA Public Health Advisory (October 15, 2004). "Suicidality in Children and Adolescents Being Treated With Antidepressant Medication," Vol. 2004 (2004)
36. Frances A.J., Kahn D.A., Carpenter D., Docherty J.P., and Donovan S.L. The Expert Consensus Guidelines for treating depression in bipolar disorder. J. Clin. Psychiatry 59 Suppl. 4 (1998) 73-79
37. Franchini L., Gasperini M., Perez J., Smeraldi E., and Zanardi R. A double-blind study of long-term treatment with sertraline or fluvoxamine for prevention of highly recurrent unipolar depression. J. Clin. Psychiatry 58 (1997) 104-107
38. Frank E., Kupfer D.J., Perel J.M., Cornes C., Jarrett D.B., Mallinger A.G., Thase M.E., McEachran A.B., and Grochocinski V.J. Three-year outcomes for maintenance therapies in recurrent depression. Arch. Gen. Psychiatry 47 (1990) 1093-1099
39. Frazer A. Pharmacology of antidepressants. J. Clin. Psychopharmacol. 17 Suppl. 1 (1997) 2S-18S
40. Geller B., Fox L.W., and Fletcher M. Effect of tricyclic antidepressants on switching to mania and on the onset of bipolarity in depressed 6- to 12-year-olds. J. Am. Acad. Child Adolesc. Psychiatry 32 (1993) 43-50
41. Geller D.A., Hoog S.L., Heiligenstein J.H., Ricardi R.K., Tamura R., Kluszynski S., and Jacobson J.G. Fluoxetine treatment for obsessive-compulsive disorder in children and adolescents: A placebo-controlled clinical trial. J. Am. Acad. Child Adolesc. Psychiatry 40 (2001) 773-779
42. Geller B., Tillman R., Craney J.L., and Bolhofner K. Four-year prospective outcome and natural history of mania in children with a prepubertal and early adolescent bipolar disorder phenotype. Arch. Gen. Psychiatry 61 (2004) 459-467
43. Geller B., Williams M., Zimerman B., Frazier J., Beringer L., and Warner K.L. Prepubertal and early adolescent bipolarity differentiate from ADHD by manic symptoms, grandiose delusions, ultra-rapid or ultradian cycling. J. Affect. Disord. 51 (1998) 81-91
44. Geller B., Zimerman B., Williams M., Bolhofner K., and Craney J.L. Bipolar disorder at prospective follow-up of adults who had prepubertal major depressive disorder. Am. J. Psychiatry 158 (2001) 125-127
45. Ghaemi S.N., Hsu D.J., Soldani F., and Goodwin F.K. Antidepressants in bipolar disorder: The case for caution. Bipolar Disord. 5 (2003) 421-433
46. Ghaemi S.N., Lenox M.S., and Baldessarini R.J. Effectiveness and safety of long-term antidepressant treatment in bipolar disorder. J. Clin. Psychiatry 62 (2001) 565-569
47. Ghaemi S.N., Rosenquist K.J., Ko J.Y., Baldassano C.F., Kontos N.J., and Baldessarini R.J. Antidepressant treatment in bipolar versus unipolar depression. Am. J. Psychiatry 161 (2004) 163-165
48. Ghaemi S.N., Soldani F., and Hsu D.J. Commentary. Int. J. Neuropsychopharmacol. 6 (2003) 303-308
49. Ghaziuddin M. Mania induced by sertraline in a prepubertal child. Am. J. Psychiatry 151 (1994) 944
50. Goddard G.V., McIntyre D.C., and Leech C.K. A permanent change in brain function resulting from daily electrical stimulation. Exp. Neurol. 25 (1969) 295-330
51. Goldberg J.F., and Harrow M. Kindling in bipolar disorders: A longitudinal follow-up study. Biol. Psychiatry 35 (1994) 70-72
52. Goldberg J.F., and Truman C.J. Antidepressant-induced mania: An overview of current controversies. Bipolar Disord. 5 (2003) 407-420
53. Goldberg J.F., and Whiteside J.E. The association between substance abuse and antidepressant-induced mania in bipolar disorder: A preliminary study. J. Clin. Psychiatry 63 (2002) 791-795
54. Goldstein T.R., Frye M.A., Denicoff K.D., Smith-Jackson E., Leverich G.S., Bryan A.L., Ali S.O., and Post R.M. Antidepressant discontinuation-related mania: Critical prospective observation and theoretical implications in bipolar disorder. J. Clin. Psychiatry 60 (1999) 563-567 ; quiz 568-569.
55. Goodwin F.K., and Jamison K.R. "Manic-Depressive Illness." (1990), Oxford University Press, New York
56. Greenhill L.L., Vitiello B., Riddle M.A., Fisher P., Shockey E., March J.S., Levine J., Fried J., Abikoff H., Zito J.M., McCracken J.T., Findling R.L., Robinson J., Cooper T.B., Davies M., Varipatis E., Labellarte M.J., Scahill L., Walkup J.T., Capasso L., and Rosengarten J. Review of safety assessment methods used in pediatric psychopharmacology. J. Am. Acad. Child Adolesc. Psychiatry 42 (2003) 627-633
57. Grubbs J.H. SSRI-induced mania. J. Am. Acad. Child Adolesc. Psychiatry 36 (1997) 445
58. Harrington R., Fudge H., Rutter M., Pickles A., and Hill J. Adult outcomes of childhood and adolescent depression. I. Psychiatric status. Arch. Gen. Psychiatry 47 (1990) 465-473
59. Hazell P., O'Connell D., Heathcote D., Robertson J., and Henry D. Efficacy of tricyclic drugs in treating child and adolescent depression: A meta-analysis. BMG 310 (1995) 897-901
60. Heils A., Teufel A., Petri S., Stober G., Riederer P., Bengel D., and Lesch K.P. Allelic variation of human serotonin transporter gene expression. J. Neurochem. 66 (1996) 2621-2624
61. Heimann S.W., and March J.S. SSRI-induced mania. J. Am. Acad. Child Adolesc. Psychiatry 35 (1996) 4
62. Henry C., Sorbara F., Lacoste J., Gindre C., and Leboyer M. Antidepressant-induced mania in bipolar patients: Identification of risk factors. J. Clin. Psychiatry 62 (2001) 249-255
63. Hirschfeld R.M. Clinical importance of long-term antidepressant treatment. Br. J. Psychiatry 42 Suppl. (2001) S4-S8
64. Holmes A., Lit Q., Murphy D.L., Gold E., and Crawley J.N. Abnormal anxiety-related behavior in serotonin transporter null mutant mice: The influence of genetic background. Genes Brain Behav. 2 (2003) 365-380
65. Howland R.H. Induction of mania with serotonin reuptake inhibitors. J. Clin. Psychopharmacol. 16 (1996) 425-427
66. Jensen P.S., Bhatara V.S., Vitiello B., Hoagwood K., Feil M., and Burke L.B. Psychoactive medication prescribing practices for U.S. children: Gaps between research and clinical practice. J. Am. Acad. Child Adolesc. Psychiatry 38 (1999) 557-565
67. Judd L.L., Akiskal H.S., Schettler P.J., Endicott J., Maser J., Solomon D.A., Leon A.C., Rice J.A., and Keller M.B. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch. Gen. Psychiatry 59 (2002) 530-537
68. Jureidini J.N., Doecke C.J., Mansfield P.R., Haby M.M., Menkes D.B., and Tonkin A.L. Efficacy and safety of antidepressants for children and adolescents. BMJ 328 (2004) 879-883
69. Kat H. More on SSRI-induced mania. J. Am. Acad. Child Adolesc. Psychiatry 35 (1996) 975
70. Keller M.B., Kocsis J.H., Thase M.E., Gelenberg A.J., Rush A.J., Koran L., Schatzberg A., Russell J., Hirschfeld R., Klein D., McCullough J.P., Fawcett J.A., Kornstein S., LaVange L., and Harrison W. Maintenance phase efficacy of sertraline for chronic depression: A randomized controlled trial. JAMA 280 (1998) 1665-1672
71. Keller M.B., Lavori P.W., Mueller T.I., Endicott J., Coryell W., Hirschfeld R.M., and Shea T. Time to recovery, chronicity, and levels of psychopathology in major depression. A 5-year prospective follow-up of 431 subjects. Arch. Gen. Psychiatry 49 (1992) 809-816
72. Keller M.B., Ryan N.D., Strober M., Klein R.G., Kutcher S.P., Birmaher B., Hagino O.R., Koplewicz H., Carlson G.A., Clarke G.N., Emslie G.J., Feinberg D., Geller B., Kusumakar V., Papatheodorou G., Sack W.H., Sweeney M., Wagner K.D., Weller E.B., Winters N.C., Oakes R., and McCafferty J.P. Efficacy of paroxetine in the treatment of adolescent major depression: A randomized, controlled trial. J. Am. Acad. Child Adolesc. Psychiatry 40 (2001) 762-772
73. Kelsoe J.R. Promoter prognostication: The serotonin transporter gene and antidepressant response. Mol. Psychiatry 3 (1998) 475-476
74. Kendler K.S., Thornton L.M., and Gardner C.O. Genetic risk, number of previous depressive episodes, and stressful life events in predicting onset of major depression. Am. J. Psychiatry 158 (2001) 582-586
75. Kessler R.C., McGonagle K.A., Zhao S., Nelson C.B., Hughes M., Eshleman S., Wittchen H.U., and Kendler K.S. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch. Gen. Psychiatry 51 (1994) 8-19
76. Kline N.S. Clinical experience with iproniazid (marsilid). J. Clin. Exp. Psychopathol. 19 (1958) 72-78 ; discussion 78-79.
77. Kukopulos A., Caliari B., Tundo A., Minnai G., Floris G., Reginaldi D., and Tondo L. Rapid cyclers, temperament, and antidepressants. Compr. Psychiatry 24 (1983) 249-258
78. Leverich G.S., Nolen W.A., Rush A.J., McElroy S.L., Keck P.E., Denicoff K.D., Suppes T., Altshuler L.L., Kupka R., Kramlinger K.G., and Post R.M. The Stanley Foundation Bipolar Treatment Outcome Network. I. Longitudinal methodology. J. Affect. Disord. 67 (2001) 33-44
79. Lewin B. "Genes VII." (2000), Oxford University Press, New York
80. Liebowitz M.R., Turner S.M., Piacentini J., Beidel D.C., Clarvit S.R., Davies S.O., Graae F., Jaffer M., Lin S.H., Sallee F.R., Schmidt A.B., and Simpson H.B. Fluoxetine in children and adolescents with OCD: A placebo-controlled trial. J. Am. Acad. Child Adolesc. Psychiatry 41 (2002) 1431-1438
81. Lucey J.V., O'Keane V., Butcher G., Clare A.W., and Dinan T.G. Cortisol and prolactin responses to d-fenfluramine in non-depressed patients with obsessive-compulsive disorder: A comparison with depressed and healthy controls. Br. J. Psychiatry 161 (1992) 517-521
82. Maj M., Pirozzi R., Magliano L., and Bartoli L. The prognostic significance of "switching" in patients with bipolar disorder: A 10-year prospective follow-up study. Am. J. Psychiatry 159 (2002) 1711-1717
83. Mann J.J. Loss of antidepressant effect with long-term monoamine oxidase inhibitor treatment without loss of monoamine oxidase inhibition. J. Clin. Psychopharmacol. 3 (1983) 363-366
84. March J., Silva S., Petrycki S., Curry J., Wells K., Fairbank J., Burns B., Domino M., McNulty S., Vitiello B., and Severe J. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. JAMA 292 (2004) 807-820
85. March J.S., Biederman J., Wolkow R., Safferman A., Mardekian J., Cook E.H., Cutler N.R., Dominguez R., Ferguson J., Muller B., Riesenberg R., Rosenthal M., Sallee F.R., Wagner K.D., and Steiner H. Sertraline in children and adolescents with obsessive-compulsive disorder: A multicenter randomized controlled trial. JAMA 280 (1998) 1752-1756
86. March J.S., Silva S.G., Compton S., Anthony G., DeVeaugh-Geiss J., Califf R., and Krishnan R. The Child and Adolescent Psychiatry Trials Network (CAPTN). J. Am. Acad. Child. Adolesc. Psychiatry 43 (2004) 515-518
87. Martin A., Young C., Leckman J., Mukonoweshuro C., Rosenheck R., and Leslie D. In Reply. Arch Ped Adolesc. Med. 159 (2005) 298-299 (to comment by Baldessarini, Hennen, Faedda, et al. 2005).
88. Martin A., Young C., Leckman J.F., Mukonoweshuro C., Rosenheck R., and Leslie D. Age effects on antidepressant-induced manic conversion. Arch. Pediatr. Adolesc. Med. 158 (2004) 773-780
89. McClellan J., and Werry J. Practice parameters for the assessment and treatment of children and adolescents with bipolar disorder. J. Am. Acad. Child. Adolesc. Psychiatry 36 (1997) 157S-176S
90. McGrath P.J., Stewart J.W., Tricamo E., Nunes E.N., and Quitkin F.M. Paradoxical mood shifts to euthymia or hypomania upon withdrawal of antidepressant agents. J. Clin. Psychopharmacol. 13 (1993) 224-225
91. Mirin S.M., Schatzberg A.F., and Creasey D.E. Hypomania and mania after withdrawal of tricyclic antidepressants. Am. J. Psychiatry 138 (1981) 87-89
92. Mueller T.I., Leon A.C., Keller M.B., Solomon D.A., Endicott J., Coryell W., Warshaw M., and Maser J.D. Recurrence after recovery from major depressive disorder during 15 years of observational follow-up. Am. J. Psychiatry 156 (1999) 1000-1006
93. Mundo E., Walker M., Cate T., Macciardi F., and Kennedy J.L. The role of serotonin transporter protein gene in antidepressant-induced mania in bipolar disorder: Preliminary findings. Arch. Gen. Psychiatry 58 (2001) 539-544
94. Nasrallah H.A., Lyskowksi J., and Schroeder D. TCA-induced mania: Differences between switchers and nonswitchers. Biol. Psychiatry 17 (1982) 271-274
95. Nestler E.J. Cellular and molecular mechanisms of drug addiction. In: Charney D.S., and Nestler E.J. (Eds). "Neurobiology of Mental Illness" (2004), Oxford University Press, New York 698-709
96. Norrholm S.D., and Ouimet C.C. Chronic fluoxetine administration to juvenile rats prevents age-associated dendritic spine proliferation in hippocampus. Brain Res. 883 (2000) 205-215
97. Oller S., Masoliver E., Menoyo A., Perez V., Grasa E., Baiget M., Puigdemont D., and Alvarez E. The 5′-HTTLPR polymorphism in the SCL6A4 is associated with antideprsesant induced mania in bipolar disorder. Paper presented at the London Bipolar Conference, 2003 (2003)
98. Peters A.P.S., and de Webster H.F. "The Fine Structure of the Nervous System: The Neurons and Supporting Cells." (1976), Saunders, Philadelphia, PA
99. Post R.M. Transduction of psychosocial stress into the neurobiology of recurrent affective disorder. Am. J. Psychiatry 149 (1992) 999-1010
100. Post R., Denicoff K., Leverich G., and Frye M.A. Drug-induced switching in bipolar disorder; epidemiology and therapeutic implications. CNS Drugs 8 (1997) 351-365
101. Post R.M., Leverich G.S., Nolen W.A., Kupka R.W., Altshuler L.L., Frye M.A., Suppes T., McElroy S., Keck P., Grunze H., and Walden J. A re-evaluation of the role of antidepressants in the treatment of bipolar depression: Data from the Stanley Foundation Bipolar Network. Bipolar Disord. 5 (2003) 396-406
102. Post R.M., Rubinow D.R., and Ballenger J.C. Conditioning and sensitisation in the longitudinal course of affective illness. Br. J. Psychiatry 149 (1986) 191-201
103. Post R.M., and Weiss S.R. Sensitization, kindling, and anticonvulsants in mania. J. Clin. Psychiatry 50 Suppl. (1989) 23-30 ; discussion 45-47.
104. Pravin D., Srinath S., Girimaji S., and Seshadri S.P. Citalopram and mania. J. Am. Acad. Child. Adolesc. Psychiatry 43 (2004) 791
105. Prien R.F., Klett C.J., and Caffey Jr. E.M. Lithium carbonate and imipramine in prevention of affective episodes. A comparison in recurrent affective illness. Arch. Gen. Psychiatry 29 (1973) 420-425
106. Prien R.F., Kupfer D.J., Mansky P.A., Small J.G., Tuason V.B., Voss C.B., and Johnson W.E. Drug therapy in the prevention of recurrences in unipolar and bipolar affective disorders. Report of the NIMH Collaborative Study Group comparing lithium carbonate, imipramine, and a lithium carbonate-imipramine combination. Arch. Gen. Psychiatry 41 (1984) 1096-1104
107. Quitkin F.M., Kane J., Rifkin A., Ramos-Lorenzi J.R., and Nayak D.V. Prophylactic lithium carbonate with and without imipramine for bipolar 1 patients. A double-blind study. Arch. Gen. Psychiatry 38 (1981) 902-907
108. Regier D.A., Narrow W.E., Rae D.S., Manderscheid R.W., Locke B.Z., and Goodwin F.K. The de facto US mental and addictive disorders service system. Epidemiologic catchment area prospective 1-year prevalence rates of disorders and services. Arch. Gen. Psychiatry 50 (1993) 85-94
109. Reichart C.G., and Nolen W.A. Earlier onset of bipolar disorder in children by antidepressants or stimulants? An hypothesis. J. Affect. Disord. 78 (2004) 81-84
110. Reimherr F.W., Amsterdam J.D., Quitkin F.M., Rosenbaum J.F., Fava M., Zajecka J., Beasley Jr. C.M., Michelson D., Roback P., and Sundell K. Optimal length of continuation therapy in depression: A prospective assessment during long-term fluoxetine treatment. Am. J. Psychiatry 155 (1998) 1247-1253
111. Rouillon F., Lejoyeux M., and Filteau M. Unwanted effects of long term treatment. In: Montgomery S., and Rouillon F. (Eds). "Long Term Treatment of Depression" (1992), Wiley, New York
112. Rousseva A., Henry C., van den Bulke D., Fournier G., Laplanche J.L., Leboyer M., Bellivier F., Aubry J.M., Baud P., Boucherie M., Buresi C., Ferrero F., and Malafosse A. Antidepressant-induced mania, rapid cycling and the serotonin transporter gene polymorphism. Pharmacogenomics J. 3 (2003) 101-104
113. Sachs G.S., Lafer B., Stoll A.L., Banov M., Thibault A.B., Tohen M., and Rosenbaum J.F. A double-blind trial of bupropion versus desipramine for bipolar depression. J. Clin. Psychiatry 55 (1994) 391-393
114. Safer D.J., Zito J.M., and Fine E.M. Increased methylphenidate usage for attention deficit disorder in the 1990s. Pediatrics 98 (1996) 1084-1088
115. Schirm E., Tobi H., Zito J.M., and de Jong-van den Berg L.T. Psychotropic medication in children: A study from the Netherlands. Pediatrics 108 (2001) E25
116. Schmidt M.E., Fava M., Zhang S., Gonzales J., Raute N.J., and Judge R. Treatment approaches to major depressive disorder relapse. Part 1: Dose increase. Psychother. Psychosom. 71 (2002) 190-194
117. Sharma V. Venlafaxine: Loss of antidepressant effect and its management. J. Clin. Psychiatry 59 (1998) 381-382
118. Sharma V. Loss of response to antidepressants and subsequent refractoriness: Diagnostic issues in a retrospective case series. J. Affect. Disord. 64 (2001) 99-106
119. Smeraldi E., Zanardi R., Benedetti F., Di Bella D., Perez J., and Catalano M. Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol. Psychiatry 3 (1998) 508-511
120. Soutullo C.A., DelBello M.P., Ochsner J.E., McElroy S.L., Taylor S.A., Strakowski S.M., and Keck Jr. P.E. Severity of bipolarity in hospitalized manic adolescents with history of stimulant or antidepressant treatment. J. Affect. Disord. 70 (2002) 323-327
121. Stoll A.L., Mayer P.V., Kolbrener M., Goldstein E., Suplit B., Lucier J., Cohen B.M., and Tohen M. Antidepressant-associated mania: A controlled comparison with spontaneous mania. Am. J. Psychiatry 151 (1994) 1642-1645
122. Strober M., and Carlson G. Bipolar illness in adolescents with major depression: Clinical, genetic, and psychopharmacologic predictors in a three- to four-year prospective follow-up investigation. Arch. Gen. Psychiatry 39 (1982) 549-555
123. Verhulst F.C., van der Ende J., Ferdinand R.F., and Kasius M.C. The prevalence of DSM-III-R diagnoses in a national sample of Dutch adolescents. Arch. Gen. Psychiatry 54 (1997) 329-336
124. Versiani M., Mehilane L., Gaszner P., and Arnaud-Castiglioni R. Reboxetine, a unique selective NRI, prevents relapse and recurrence in long-term treatment of major depressive disorder. J. Clin. Psychiatry 60 (1999) 400-406
125. Wagner K.D., Ambrosini P., Rynn M., Wohlberg C., Yang R., Greenbaum M.S., Childress A., Donnelly C., and Deas D. Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder: Two randomized controlled trials. JAMA 290 (2003) 1033-1041
126. Wagner K.D., Robb A.S., Findling R.L., Jin J., Gutierrez M.M., and Heydorn W.E. A randomized, placebo-controlled trial of citalopram for the treatment of major depression in children and adolescents. Am. J. Psychiatry 161 (2004) 1079-1083
127. Walkup J., Labellarte M., Riddle M.A., Pine D.S., Greenhill L., Fairbanks J., Klein R., Davies M., Sweeney M., Abikoff H., Hack S., Klee B., Bergman R.L., Lynn D., McCracken J., March J., Gammon P., Vitiello B., Ritz L., and Roper M. Treatment of pediatric anxiety disorders: An open-label extension of the research units on pediatric psychopharmacology anxiety study. J. Child Adolesc. Psychopharmacol. 12 (2002) 175-188
128. Walkup J.T., Lafellarte M.J., Riddle M.A., Pine D.S., Greenhill L., Klein R., Davies M., Sweeney M., Abikoff H., Hack S., Klee B., McCracken J., Bergman L., Piacentini J., March J., Compton S., Robinson J., O'Hara T., and Baker S. Fluvoxamine for the treatment of anxiey disorders in children and adolescents. N. Engl. J. Med. 344 (2001) 1279-1285
129. Wegerer V., Moll G.H., Bagli M., Rothenberger A., Ruther E., and Huether G. Persistently increased density of serotonin transporters in the frontal cortex of rats treated with fluoxetine during early juvenile life. J. Child Adolesc. Psychopharmacol. 9 (1999) 13-24 ; discussion 25-26.
130. Wehr T.A., and Goodwin F.K. Rapid cycling in manic-depressives induced by tricyclic antidepressants. Arch. Gen. Psychiatry 36 (1979) 555-559
131. Wehr T.A., Sack D.A., Rosenthal N.E., and Cowdry R.W. Rapid cycling affective disorder: Contributing factors and treatment responses in 51 patients. Am. J. Psychiatry 145 (1988) 179-184
132. Wilens T.E., Biederman J., Kwon A., Chase R., Greenberg L., Mick E., and Spencer T.J. A systematic chart review of the nature of psychiatric adverse events in children and adolescents treated with selective serotonin reuptake inhibitors. J. Child Adolesc. Psychopharmacol. 13 (2003) 143-152
133. Wozniak J., Biederman J., Kiely K., Ablon J.S., Faraone S.V., Mundy E., and Mennin D. Mania-like symptoms suggestive of childhood-onset bipolar disorder in clinically referred children. J. Am. Acad. Child Adolesc. Psychiatry 34 (1995) 867-876
134. ®ER released on August 22, 2003 (2003)
135. Zajecka J., Tracy K.A., and Mitchell S. Discontinuation symptoms after treatment with serotonin reuptake inhibitors: A literature review. J. Clin. Psychiatry 58 (1997) 291-297